HomeAI · summaries
Storia in 10 fonti
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it could be swallowe...
- ·
wiwo.de
Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics
Der Pharmariese aus den USA plant offenbar den Kauf von Apogee Therapeutics. Das Angebot stellt einen deutlichen Aufschlag dar.
- ·
expansion.com
AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones
Seg�n los t�rminos de un potencial acuerdo que est� en fase avanzada y que podr�a anunciarse el lunes, AbbVie pagar� un prima cercana al 60% respecto al cierre en Bolsa de...
- ·
valor.globo.com
FT: AbbVie está perto de comprar Apogee Therapeutics por US$ 11 bi
Negócio chega em meio a aumento de compras de companhias de biotecnologia e ao interesse das grandes farmacêuticas para reforçar desenvolvimento de remédios
- ·
biopharmadive.com
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…
- ·
endpoints.news
AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.
- ·
statnews.com
AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
- ·
Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar
AbbVie stärkt mit der Übernahme von Apogee Therapeutics sein Immunologie-Portfolio und setzt auf neue Wachstumstreiber.
- ·
benzinga.com
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
- ·
investors.com
AbbVie Goes On The Offensive With $10.9 Billion Takeover
The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.
- ·
AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares
Seg�n los t�rminos del acuerdo, AbbVie pagar� un prima cercana al 50% respecto al cierre en Bolsa de Apogee Therapeutics el pasado jueves, ya que el viernes no hubo sesi�n en...
- ·
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monda
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM,…
- ·
milanofinanza.it
AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News
<p>AbbVie ha raggiunto un accordo per l'acquisizione di Apogee Therapeutics per circa 10,9 miliardi di dollari in contanti, un'operazione che rafforza il portafoglio di farmaci…
- ·
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.